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Background: Limited data are available on the outcome of antiepileptic drug treatment response in patients of
Chinese Han ethnicity with newly diagnosed epilepsy. We sought to explore the prognosis with antiepileptic drug
treatment and to identify the predictors of poor drug control of seizures in these patients.
Methods: For at least 2 years, we prospectively followed up a cohort of patients with newly diagnosed epilepsy
and analyzed the response to each antiepileptic drug. Cumulative risk for seizure relapse after initial remission
achieved was estimated. The patients were divided into two groups (poor and good control) and compared for
clinical characteristics.
Results: A total of 180 patients were included. Early remission was reached in 125 (69.44%) patients, 19 (10.56%)
patients entered late remission, while 36 (20%) patients failed to achieve remission. The relapse rates were 19.5% at
2 years and 31.9% at 3 years of the follow-up. The response rates of the first throughout the fourth treatment
regimens were 60.0%, 16.1%, 2.8%, and 0.6%, respectively. Multiple seizure types and changes in seizure type during
treatment were significantly (p = 0.013 and 0.047, respectively) associated with a poor control.
Conclusions: The prognosis of the majority of patients with newly diagnosed epilepsy is good and the clinical
pattern of epilepsy during treatment is complex. The chances of seizure control declines with each subsequent
treatment regimen. The prognosis for patients with multiple seizure types and seizure type changes during
treatment is unfavorable.
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Epilepsy is one of the most common neurological condi-
tions. Seventy million people have epilepsy, with the inci-
dence of 34 – 76 of newly diagnosed cases per 100,000 [1].
While the majority of patients with epilepsy respond well
to one antiepileptic drug (AED), nearly up to one third of
patients respond poorly to antiepileptic therapy with two
or more AEDs, or develop drug-resistant epilepsy (DRE).
Uncontrolled epilepsy and overdose of AEDs are associ-
ated with adverse effects, such as cognitive deterioration,
psychosocial dysfunction, and increased morbidity and
mortality [2,3]. Therefore, early identification of patients
who are at high risk of developing DRE is crucial.
While the risk factors influencing the prognosis of epi-
lepsy have begun to be appreciated [4-7], limited data are* Correspondence: diqing@medmail.com.cn
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stated.available on the clinical patterns of treatment response in
newly diagnosed epilepsy. It is important to understand
the different clinical patterns of response to AED treat-
ment, ideally by following the outcomes once the treat-
ment has been initiated. However, some current studies
were limited by selection bias toward patients with drug-
resistant epilepsy who had already failed at least two drug
regimens [8,9]. Further, epilepsy has heterogeneous eti-
ology and outcomes. The disease patterns in individual pa-
tients may be genetically determined and, thus, may vary
among patients from different ethnic backgrounds. Cur-
rently, a large number of epileptic individuals (estimated
over six million sufferers) live in China [10], but there is
no data in this population, necessitating studies on this
field.
In the present study, we prospectively followed up a
cohort of patients in east China with newly diagnosed
epilepsy to explore the prognosis with antiepileptic drugLtd. This is an Open Access article distributed under the terms of the Creative
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control of seizures in these patients.
Methods
Patients
In 2005, the International League against Epilepsy
(ILAE) re-defined epilepsy as a disorder of the brain
characterized by an enduring predisposition to generate
epileptic seizures and by the neurobiologic, cognitive,
psychological, and social consequences of this condition.
The definition of epilepsy requires the occurrence of at
least one epileptic seizure [11]. In our study, patients
who had never previously received treatment with AED
and who met the new definition of epilepsy were
recruited from the Neurology Clinic of Nanjing Brain
Hospital between January 2000 and June 2010. The pa-
tients were prospectively followed up until the end of
June 2012, i.e., for at least two years. Informed consent
was obtained from each participant. The study was ap-
proved by the Nanjing Brain Hospital affiliated to Nanjing
Medical University Ethics Committee.
During the first visit, we collected demographic and
clinical information from patients and their relatives
using a structured questionnaire developed in-house,
and performed general physical and neurologic examina-
tions. Electroencephalography (EEG) was performed in
patients to facilitate classification of the epilepsy, includ-
ing video EEG monitoring within 24 hours and standard
stimulation procedures (photic stimulation and hyper-
ventilation). Magnetic resonance imaging (MRI) of the
brain was performed using a high resolution 3.0 T. All
MRI scans were conducted by a specialized neuroradiol-
ogist using standard MR protocols to screen for under-
lying structural abnormalities that might have caused
the epilepsy. Patients with serious systemic illnesses or
seizures provoked by external factors, e.g., alcohol with-
drawal, were excluded at the time of analysis.
Possible determinants were obtained prior to diagnosis
and initiation of the treatment and included patients’
gender, age at the seizure onset, duration of epilepsy,
seizure frequency, presence of seizures during sleep,
seizure type, changes in seizure type during treatment,
etiology (i.e., genetic, structural/metabolic such as head
trauma, tumor, stroke, infection), family history of epi-
lepsy, febrile seizures, history of brain injury, early men-
tal retardation, and brain MRI and EEG findings. For
either generalized onset epilepsies or focal onset epilep-
sies, seizures would be presented in different forms in
clinical phenomenology. Multiple seizure types may co-
exist and the type may change during different periods
in some epilepsy syndromes. So, the two factors were
used to predict the outcome of epilepsy in our study.
Duration of epilepsy was defined as the period from the
seizure onset to the end of follow-up. Seizure frequencywas defined as the mean monthly seizure frequency
within 1 year before treatment. A positive family history
was defined as the presence of epilepsy in first-degree
relatives (i.e., parents, siblings, and children).
Definitions
According to the ILAE classification of epileptic seizures
[12], seizure types were categorized into generalized
(tonic, clonic, or tonic–clonic) or focal (simple or com-
plex partial). The epilepsy syndrome was classified as
genetic, structural/metabolic, unknown cause, using the
ILAE classification criteria of epilepsies and epileptic
syndromes [13].
Outcomes were obtained from personal interviews.
Remission was defined as an achievement of at least one
year free of seizures, and categorized into early and late
remissions. Early remission was achieved within first
year of treatment initiation, as opposed to late remission,
which was achieved after more than first year of treat-
ment. Terminal remission was regarded as remission
achieved at the end of follow-up. Relapse described the
occurrence of repeated seizures after remission achieved.
According to the definition proposed by the ILAE [14],
DRE was defined as the failure of two well-tolerated, and
appropriately chosen and used AED schedules, whether
as monotherapies or in combination, to achieve a
sustained seizure freedom for either one year or for a
period equal to three times of the pre-intervention inter-
seizure time, whichever was longer.
Treatment
The treatment given in the present study was done as
part of standard care. Patients were prescribed AEDs
according to their seizure type, personal profiles (i.e.,
sex, age)and drug characteristics (i.e., efficacy, side ef-
fects and interaction profiles). The AEDs we have pre-
scribed in the study include carbamazepine, valproate
sodium, oxcarbazepine, lamotrigine and topiramate.
Monotherapy was tried initially in all patients. AEDs
were increased to the maximum tolerated doses. Patients
who continued to experience seizures despite at high
doses of AED were designated as treatment failures be-
cause of lack of efficacy. Those developing idiosyncratic
reactions or experiencing intolerable side effects at low
AED dosage were deemed to have failed treatment be-
cause of adverse effects. If the first prescribed AED is
poorly tolerated at low dosage or fails to improve seizure
control, patients would be prescribed another drug. If
the first AED is well-tolerated but does not completely
abolish the seizures, combination therapy would be ap-
plied. Compliance with the treatment regimen was
monitored at the clinic. Patients who did not comply
with the treatment regimen were excluded from the
study.
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Patients were evaluated at 4 weeks after the treatment
started and then at 3-month intervals thereafter. At each
follow-up visit, seizure frequency, drug doses, response
to drug therapy and compliance were routinely recorded
and adjusted, as dictated by clinical circumstances. The
follow-up data were collected on a data record sheet
specially developed for the purpose of this study.
The final evaluation of seizure control was performed
after a minimum of 2 years of follow-up. For compari-
son, we divided patients into two groups. Patients who
met the definition of DRE were considered to have a
poor prognosis. The remaining patients were labeled as
having a good prognosis.Statistical analysis
All analyses were performed with SPSS 13.0 software
(IBM, Chicago, USA). The two-tailed chi-square or Fisher’s
exact tests were used for comparison of categorical data,
while the Student’s t test or the Mann–Whitney test were
used for comparison of continuous data. Among those pa-
tients who achieved one year seizure remission, Kaplan-
Meier analyses were used to estimate the cumulative risk
for the seizure relapse. Logistic regression was used to in-
vestigate covariates of interest, first individually in univari-
ate models and then together in a multivariate model. The
odds ratio (OR) and 95% confidence interval (CI) were cal-
culated. The two-tailed p value of < 0.05 was considered
as statistically significant.Results
Patient characteristics
A total of 212 patients were diagnosed with epilepsy and
none had previously received an AED for any indication.
Thirty-two patients (15.1%) were excluded from analysis
because of lack of sufficient follow-up information. At
the end of the follow-up period, outcomes were known
for the remaining 180 (84.9%) patients. EEG was
performed for each patient and 35 of them accepted
video EEG monitoring. The median duration of the
follow-up was 5 years (range 2 – 10 years). Among the
180 patients included in the study, 94 (52.2%) were male.
The median (range) age at referral was 19 (6 – 71) years,
and the median (range) age at the onset of epilepsy was
13 (1 – 65) years. A slightly higher number of patients
(56.1%) had focal seizures, while the remaining patients
(43.9%) presented with generalized seizures. Epilepsy
was classified as genetic in 47 (26.1%), structural/meta-
bolic in 55 (30.6%), and unknown cause in 78 (43.3%)
patients. Structural damage of the brain was caused by
stroke, trauma, tumor, infection, tuberous sclerosis and
cortical malformations. Metabolic etiologies mainly in-
clude mitochondrial disorders.Prognosis of patients with newly diagnosed epilepsy
In total, 144 (80%) patients remained seizure-free for at
least one year. The remaining 36 (20%) patients never
experienced a one year remission while continuing AED
therapy (Figure 1).
Early remission
Early remission was reached in 125 (69.44%) out of 180
patients. Despite a good initial outcome, relapse oc-
curred in 53 patients. The remaining 72 patients went
into terminal remission with no relapse until the end of
the follow-up period.
Late remission
Nineteen (10.56%) out of 180 patients entered late re-
mission. One or more relapses were noted in 2 (1.11%)
patients, but 17 (9.45%) patients remained in terminal
remission without any relapse.
Remitting course of epilepsy
Terminal remission uninterrupted by relapse was noted
in 72 (40%) patients in the early remission group and in
17 (9.45%) patients who entered the late remission
phase. Overall, 89 out of 180 (49.44%) patients reached
the terminal remission without relapse indicating a re-
mitting course of epilepsy.
Remitting–relapsing course of epilepsy
Out of 144 (30.55%) patients who achieved a one year
remission, the events of relapse occurred in 55 patients,
indicating a remitting–relapsing course of epilepsy. A
Kaplan-Meier plot of the time to relapse showed a rate
of 19.5% at 2 years and 31.9% at 3 years of follow-up
(Figure 2).
Worsening course of epilepsy
Terminal remission after relapse was noted in 19 of 53
(10.55%) patients following early remission. None of the
2 patients, whose late remission was followed by relapse,
regained terminal remission. There were 34 out of 125
(18.89%) patients, whose early remission was followed by
relapse, and 2 out of 19 (1.11%) patients, whose late re-
mission was followed by relapse; these 36 patients never
regained terminal remission, resulting in a total of 20%
(36/180) patients with a worsening course of epilepsy.
Drug resistance
In total, 36 (20%) patients never experienced a one year
remission during the AED therapy. Among them, 23
(12.78%) patients failed to achieve remission after using
at least two AEDs and were thus defined as having DRE.
The remaining 13 (7.22%) patients with no remission
only received one AED therapy and could not yet be
classified as DRE.
Figure 2 The Kaplan–Meier estimate of cumulative probability for subsequent seizure relapse. Initial remission was achieved in 144
patients, of whom 55 experience relapse. Kaplan–Meier estimates the cumulative probability of relapse during the follow-up period.
Figure 1 Outcomes for patients with newly diagnosed epilepsy. The treatment outcomes of patients were divided into three groups: early
remission (seizure-free disease achieved for at least one year within the first year of starting the therapy), late remission (seizure-free disease
achieved for at least one year after more than 1 year of therapy), and no remission ever (never achieved at least one year of seizure-free disease
during the follow-up period).
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Table 2 Clinical characteristics of patients with the newly
diagnosed epilepsy





Male gender 11 (47.8%) 83 (52.9%) 0.651
Age 17 (9 – 37) 19 (6 – 71) 0.516
Age at the seizure onset 12 (4 – 30) 13 (1 – 65) 0.822
Duration of epilepsy (months) 81 (24 – 99) 40 (24 – 110) < 0.001
Type of epilepsy 0.022
Focal seizures 18 (78.3%) 83 (52.9%)
Generalized seizures 5 (21.7%) 74 (47.1%)
Etiology 0.128
Genetic 9 (39.1%) 38 (24.2%)
Structural/metabolicor
unknown cause
14 (60.9%) 119 (75.8%)
The bold in the table indicates statistically significant data.
A good outcome was defined as a seizure-free remission for at least one year.
A poor outcome was defined as no seizure-free remission for one year. The
percentages sum up by column.
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Among 180 patients with newly diagnosed epilepsy, 144
(80%) were seizure-free for at least one year of therapy.
One-hundred eight (60%) patients achieved remission
with the first AED, while 36 (20%) patients became
seizure-free with subsequent drugs. The overall response
rates for the first, second or third treatment schedules as
proportions of the study population were 60.0%, 16.6%
and 2.8%, respectively, with just one (0.6%) patient
responding to further drug trials (Table 1).
In the remaining 72 patients who had uncontrolled
seizures, 34 (47%) patients discontinued their first drug
because of lack of efficacy, 30 (42%) because of intoler-
able adverse effects, 8 (11%) for other reasons, such as
planning a pregnancy or a change of mind about drug
treatment.
Analysis of predictors related to seizure outcome
At the end of follow-up, 23 of the 36 (12.78%) patients
who never experienced remission were defined as DRE
and classified into the poor outcome group; the remaining
157 (87.22%) patients were classified into the good out-
come group. The patients of these two groups did not dif-
fer significantly with regards to gender distribution, age,
age at the seizure onset, and etiology (Table 2).
By contrast, the duration of epilepsy was longer in the
poor outcome group compared with the good outcome
group (p < 0.001; Table 2). Further, a significantly higher
proportion of patients had focal seizures in the poor out-
come group (p = 0.022; Table 2).
Univariate logistic regression analysis of the patients in
these two groups demonstrated that poor outcome was
associated with focal seizures, multiple seizure types and
changes in seizure type during therapy (Table 3). The
multivariable logistic regression model further demon-
strated that multiple seizure types (OR=3.33, 95% CI
1.29-8.60, p = 0.013) and changes in seizure type during
treatment (OR=5.88, 95% CI 1.03-33.62, p = 0.047) were
predictive of poor outcome (Table 4).Table 1 Relationship between the number of AEDs and






Good N (%) Poor N (%)
1 119 (66.1) 108 (90.8) 11 (9.2)
2 40 (22.2) 30 (75.0) 10 (25.0)
3 14 (7.8) 5 (35.7) 9 (64.3)
4 5 (2.8) 1 (20.0) 4 (80.0)
5 2 (1.1) 0 (0) 2 (100)
Total 180 (100) 144 (80.0) 36 (20.0)
AED: antiepileptic drug. A good outcome was defined as a seizure-free
remission for at least one year. A poor outcome was defined as no seizure-free
remission for one year. Percentages of the therapy outcome sum up by row.Discussion
To date, the clinical patterns of epilepsy remain poorly
understood, although three different patterns of DRE
have been proposed [15,16]: the de novo continuous
drug resistance, reversal of drug resistance, and progres-
sion to drug resistance. If different patterns exist, their
recognition would be useful for counseling and planning
interventions for patients with epilepsy.
The results of our study showed that 144 patients
achieved remission during the follow-up period, and 17
out of 19 patients who entered late remission also
remained in terminal remission with no relapse, sug-
gesting that initial failure to enter remission cannot reli-
ably indicate a long-term failure to achieve remission. In
agreement with our data, Camfield et al. [17] found that
61% of 345 children responding to the first AED eventu-
ally went into remission. Further, 30 out of 72 (42%) chil-
dren, who failed to respond to the first AED, later
achieved remission thus suggesting that initial drug re-
sponse cannot reliably predict drug resistance. Out of 125
patients entering early remission, 91 patients remained in
remission at the end of the follow-up period, suggesting a
remitting course. Furthermore, 27.2% of the patients who
reached early remission were unable to regain remission
after relapse, indicating a progressively worsening course
of epilepsy. In 19 out of 180 (10.5%) patients, remission
was followed by relapse and return to terminal remission,
which suggested a remitting–relapsing pattern of epilepsy.
In a recent study from British, Brodie et al. [18] delineated
four temporal patterns of outcome in newly diagnosed
epilepsy: A) early and sustained seizure freedom; B) de-
layed but sustained seizure freedom; C) fluctuation
Table 3 Univariate comparison of outcomes in the newly diagnosed epilepsy
Parameter Outcome Univariate comparison
Poor (N = 23) Good (N= 157) OR 95% CI P value
Male gender 11 (47.8%) 83 (52.9%) 0.817 0.34 – 1.963 0.652
Age at the seizure onset 12 (4 – 30) 13 (1 – 65) 1.012 0.967 – 1.059 0.598
>1 seizure monthly before treatment 4 (17.4%) 26 (16.6%) 1.061 0.333 – 3.375 0.920
≥50% seizures during sleep 12 (52.5%) 81 (51.6%) 1.024 0.426 – 2.458 0.958
Focal seizures 18 (78.3%) 83 (52.9%) 3.21 1.135 – 9.073 0.028
Multiple seizure types 10 (43.5%) 27 (17.2%) 3.704 1.472 – 9.319 0.005
Changes in seizure type during treatment 3 (13.0%) 3 (1.9%) 7.70 1.454 – 40.77 0.016
Genetic epilepsy 9 (39.1%) 38 (24.2%) 2.013 0.807 – 5.019 0.133
Positive family history 2 (8.7%) 14 (8.9%) 0.973 0.206 – 4.587 0.972
Abnormal perinatal history 3 (13.0%) 11 (7.0%) 1.991 0.511 – 7.753 0.321
History of brain injury 1 (4.3%) 9 (5.7%) 0.747 0.09 – 6.19 0.787
Febrile seizures 4 (17.4%) 24 (15.3%) 1.167 0.365 – 3.731 0.795
Mental retardation 1 (4.3%) 4 (2.5%) 1.739 0.186 – 16.27 0.628
Abnormal neuroimaging 3 (13.0%) 20 (12.7%) 1.027 0.28 – 3.774 0.967
EEG abnormalities characterized by an epileptiform wave 17 (73.9%) 82 (52.2%) 2.591 0.971 – 6.919 0.057
Abnormal EEG characterized by a slow wave 8 (34.8%) 39 (24.8%) 1.614 0.636 – 4.095 0.314
The bold in the table indicates statistically significant data.
A good outcome was defined as a seizure-free remission for at least one year. A poor outcome was defined as no seizure-free remission for one year. The
percentages sum up by column.
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seizure freedom never attained. At the end of follow-up, a
total of 1,098 patients were included, 749 (68%) patients
were seizure-free. Outcome pattern A was observed in
408 (37%), pattern B in 246 (22%), pattern C in 172 (16%),
and pattern D in 272 (25%) patients. The results were
similar with our study, though the proportions of pattern
B and D were slightly higher than ours, which may be
explained by the differences in the selection criteria or
genetic background.
In our study, 144 newly diagnosed epilepsy patients
achieved initial remission with AEDs treatment for at
least one year. The majority of relapses occurred within
three years after initial one-year remission achievement.
As 48 patients were lost during follow-up, which caused
the censored data was large and the latter part of the sur-
vival plot was not very reliable, we only analyzed the data
from the first three years. As illustrated in the Kaplan-
Meier survival plot (Figure 2), the relapse rates were 19.5%
at 2 years and 31.9% at 3 years during the follow-up. WeTable 4 Multivariate logistic regression analysis for predictor
Predictor Outco
Poor (N = 23)
Multiple seizure type 10 (43.5%)
Changes in seizure type during the treatment 3 (13.0%)
The bold in the table indicates statistically significant data.
A good outcome was defined as a seizure-free remission for at least one year. A po
percentages sum up by column.have noticed that this data is different from another recent
study from British. Mohanraj and Brodie [19] have
reported that 504 of 780 patients in their study achieved
remission for at least one year; only 42 patients relapsed
during the follow-up period of 12 years. Also in that re-
port, the Kaplan-Meier plot of time to relapse showed a
rate of 10.4% after 8 years of follow-up. The higher rate of
relapse in our study may also be related to the differences
in the selection criteria or genetic background.
Uncontrolled epilepsy has an adverse impact on quality
of life [20,21]. Therefore, identification of the time point
when drug resistance occurs may be useful to develop al-
ternative interventions to prevent some forms of epilepsy
from becoming drug resistant. We do not know when
drug resistance develops in the course of epilepsy, which
may lead us to miss the optimal time for intervention [22].
There are three concurrent hypotheses about the evo-
lution of drug resistance. The de novo theory stipulates
that in most cases, drug resistance has been fully devel-
oped before the first seizure or at least before the starts of poor outcome in the newly diagnosed epilepsy
me Multivariate analysis
Good (N = 157) OR 95% CI P value
27 (17.2%) 3.33 1.29 – 8.60 0.013
3 (1.9%) 5.88 1.03 – 33.62 0.047
or outcome was defined as no seizure-free remission for one year. The
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port this hypothesis. Further, our study shows the de
novo drug resistance in 23 (12.78%) of 180 patients.
Such patients are more likely to have poor response to
the first AED prescribed. The second hypothesis indi-
cates that there is progression from remission to drug
resistance meaning that some patients develop DRE after
initially responding well to the first AED. Supporting
this, recent studies [24,25] demonstrate a substantial
proportion of epilepsy with the childhood onset that
does not become drug resistant for many years after the
onset. The third hypothesis is that drug resistance is re-
versible, i.e., it may remit and reappear during the course
of epilepsy or the associated therapy. The reverse process
is well known as an intermittent pattern in which periods
of remission are followed by periods of uncontrolled sei-
zures. Findings from randomized placebo-controlled add-
on trials indicate that a small percentage of patients with
previous drug-resistant partial epilepsy responded to the
therapy and became seizure-free during trials with new
AEDs [26]. This type of pattern also existed in our study.
As mentioned above, 27.2% of our patients entering early
remission were unable to reach remission again in the
subsequent follow-up. Such patients could not be classi-
fied as DRE according to the definition proposed by the
ILAE in 2009 [14]. In our opinion, this was not appropri-
ate because their prognosis is unfavorable. Therefore, the
definition of DRE should be revised, and the observed
time should be determined in additional studies.
An important characteristic of DRE is that most pa-
tients with intractable epilepsy are resistant to most or
all AEDs. Current AEDs do not seem to prevent or re-
verse drug resistance in most patients [16]. At present,
there are nearly 20 AEDs available to clinicians. The
number of AEDs that needs to have failed in order to
define DRE in a given patient has been debated in the
literature [6,7,27,28]. The consensus regarding the num-
ber of AED failures seems to be 2 or 3. Kwan et al. [23]
found that there was a clear negative association be-
tween the number of AED regimens tried and the
chances of achieving substantial remission. In their
study, the respective chances of achieving remission for
one year with the first, second and third AED attempts
were 47%, 13% and 1%. The findings of Mohanraj et al.
[19] were similar with the results of the aforementioned
studies. Our results showed that overall rates of achiev-
ing a one year remission with the first, second, third and
fourth AED trials were 60.0%, 16.6%, 2.8% and 0.6%, re-
spectively. None of the patients who had experienced
failure with four AED regimens became seizure-free.
Due to different study designs and the lack of a stand-
ard definition of pharmaco-resistance in the literature,
the reported incidence of DRE varies from 7% to 36.7%
[23,29-31]. To the best of our knowledge, no data hasbeen reported regarding the incidence of DRE in the
Chinese population. Therefore, we set up this investiga-
tion. Here we reported that the incidence of DRE in east
China newly diagnosed epilepsy patients was approxi-
mately 13%. In this study, 20% of the patients failed to
achieve remission, including 7% of patients were treated
with only one AED throughout the period of follow-up
(which did not meet the criteria of DRE). It is note-
worthy that the duration of follow-up will critically affect
the defined course of epilepsy, especially in terms of re-
lapsing and DRE. Some patients with a relative short
period of clinical follow-up in this study may influence
the result and the incidence of DRE. For instance, some
of the above mentioned 7% of patients may develop to
DRE in the future study with longer follow-up time.
It is widely recognized that early identification of pa-
tients who are at high risk of developing DRE is import-
ant. A number of studies were published about the
predictive factors for DRE such as the age of seizure on-
set, frequent seizures before treatment, seizure type,
early mental retardation, brain imaging and EEG abnor-
malities [5-7,23,29,30,32-36]. The two most prominent
risk factors of poor outcome identified in the present
study were multiple seizure types and change in seizure
type during treatment.
Conclusions
An array of diverse dynamic changes occurs during the
course of epilepsy. Our results show that the prognosis
of the majority of patients with newly diagnosed epilepsy
is good. The chances of seizure control will decline with
subsequent treatment regimens after the failure of the
first AED treatment. Multiple seizure types and change
in seizure type during treatment will predict the poor
control of seizures. Patients with these risk factors
should receive formal antiepileptic treatment or alterna-
tive treatments such as surgery. However, further studies
with large sample size, multi-center and long-term
follow-up are required to verify our observations.
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